schliessen

Filtern

 

Bibliotheken

Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)

The safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data have been reported. In the SPIRIT III trial, 1,0... Full description

Journal Title: The American Journal of Cardiology Mar 15, 2011, Vol.107(6), p.833
Main Author: Applegate, Robert
Other Authors: Yaqub, Manejeh , Hermiller, James , Sood, Poornima , Yu, Shui , Doostzadeh, Julie , Williams, Jerome , Farhat, Naim , Caputo, Ronald , Lansky, Alexandra , Cutlip, Donald , Sudhir, Krishnankutty , Stone, Gregg
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 00029149 ; E-ISSN: 18791913
Link: http://search.proquest.com/docview/859535509/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest859535509
title: Long-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
format: Article
creator:
  • Applegate, Robert
  • Yaqub, Manejeh
  • Hermiller, James
  • Sood, Poornima
  • Yu, Shui
  • Doostzadeh, Julie
  • Williams, Jerome
  • Farhat, Naim
  • Caputo, Ronald
  • Lansky, Alexandra
  • Cutlip, Donald
  • Sudhir, Krishnankutty
  • Stone, Gregg
subjects:
  • United States–Us
  • Cardiovascular Disease
  • Patient Safety
  • Clinical Trials
  • Stents
  • Comparative Analysis
  • Cardiology
ispartof: The American Journal of Cardiology, Mar 15, 2011, Vol.107(6), p.833
description: The safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data have been reported. In the SPIRIT III trial, 1,002 patients with up to 2 lesions in 2 coronary arteries were randomized 2:1 to EESs versus PESs at 65 United States sites. At completion of 3-year follow-up, treatment with EES compared to PES resulted in a significant 30% decrease in the primary clinical end point of target vessel failure (cardiac death, myocardial infarction, or ischemic-driven target vessel revascularization, 13.5% vs 19.2%, hazard ratio 0.70, 95% confidence interval 0.50 to 0.96, p = 0.03) and a 43% decrease in major adverse cardiovascular events, cardiac death, myocardial infarction, or ischemic-driven target lesion revascularization (9.1% vs 15.7%, hazard ratio 0.57, 95% confidence interval 0.39 to 0.83, p = 0.003). In...
language: eng
source:
identifier: ISSN: 00029149 ; E-ISSN: 18791913
fulltext: fulltext
issn:
  • 00029149
  • 0002-9149
  • 18791913
  • 1879-1913
url: Link


@attributes
ID1843422270
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid859535509
sourceidproquest
recordidTN_proquest859535509
sourcesystemPC
pqid859535509
display
typearticle
titleLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
creatorApplegate, Robert ; Yaqub, Manejeh ; Hermiller, James ; Sood, Poornima ; Yu, Shui ; Doostzadeh, Julie ; Williams, Jerome ; Farhat, Naim ; Caputo, Ronald ; Lansky, Alexandra ; Cutlip, Donald ; Sudhir, Krishnankutty ; Stone, Gregg
ispartofThe American Journal of Cardiology, Mar 15, 2011, Vol.107(6), p.833
identifierISSN: 00029149 ; E-ISSN: 18791913
subjectUnited States–Us ; Cardiovascular Disease ; Patient Safety ; Clinical Trials ; Stents ; Comparative Analysis ; Cardiology
descriptionThe safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data have been reported. In the SPIRIT III trial, 1,002 patients with up to 2 lesions in 2 coronary arteries were randomized 2:1 to EESs versus PESs at 65 United States sites. At completion of 3-year follow-up, treatment with EES compared to PES resulted in a significant 30% decrease in the primary clinical end point of target vessel failure (cardiac death, myocardial infarction, or ischemic-driven target vessel revascularization, 13.5% vs 19.2%, hazard ratio 0.70, 95% confidence interval 0.50 to 0.96, p = 0.03) and a 43% decrease in major adverse cardiovascular events, cardiac death, myocardial infarction, or ischemic-driven target lesion revascularization (9.1% vs 15.7%, hazard ratio 0.57, 95% confidence interval 0.39 to 0.83, p = 0.003). In...
languageeng
source
version5
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/859535509/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Applegate, Robert
1Yaqub, Manejeh
2Hermiller, James
3Sood, Poornima
4Yu, Shui
5Doostzadeh, Julie
6Williams, Jerome
7Farhat, Naim
8Caputo, Ronald
9Lansky, Alexandra
10Cutlip, Donald
11Sudhir, Krishnankutty
12Stone, Gregg
titleLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
descriptionThe safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data have been reported. In the SPIRIT III trial, 1,002 patients with up to 2 lesions in 2 coronary arteries were randomized 2:1 to EESs versus PESs at 65 United States sites. At completion of 3-year follow-up, treatment with EES compared to PES resulted in a significant 30% decrease in the primary clinical end point of target vessel failure (cardiac death, myocardial infarction, or ischemic-driven target vessel revascularization, 13.5% vs 19.2%, hazard ratio 0.70, 95% confidence interval 0.50 to 0.96, p = 0.03) and a 43% decrease in major adverse cardiovascular events, cardiac death, myocardial infarction, or ischemic-driven target lesion revascularization (9.1% vs 15.7%, hazard ratio 0.57, 95% confidence interval 0.39 to 0.83, p = 0.003). In...
subject
0United States–Us
1Cardiovascular Disease
2Patient Safety
3Clinical Trials
4Stents
5Comparative Analysis
6Cardiology
general
0English
1Elsevier Limited
2Medical Database
3Health & Medical Collection (Alumni edition)
4Medical Database (Alumni edition)
5Nursing & Allied Health Database (Alumni edition)
6Health & Medical Collection
7Nursing & Allied Health Database
8Sports Medicine and Education Index
9Research Library China
10Engineering Research Database
11Technology Research Database
12ProQuest Nursing & Allied Health Source
13ProQuest Research Library
14ProQuest Biological Science Collection
15ProQuest Central
16ProQuest Engineering Collection
17ProQuest Environmental Science Collection
18ProQuest Hospital Collection
19ProQuest Natural Science Collection
20ProQuest Technology Collection
21Research Library (Alumni edition)
22Hospital Premium Collection (Alumni edition)
23ProQuest SciTech Collection
24ProQuest Health & Medical Complete
25ProQuest Medical Library
26Physical Education Index
27Agricultural & Environmental Science Database
28Biological Science Database
29Materials Science & Engineering Database
30Natural Science Collection
31ProQuest Central (new)
32ProQuest Central K-12
33ProQuest Central Korea
34Research Library Prep
35SciTech Premium Collection
36Technology Collection
37Health Research Premium Collection
38Health Research Premium Collection (Alumni edition)
39ProQuest Central Essentials
40ProQuest Central China
41ProQuest One Academic
42Environmental Science Index (ProQuest)
43Biological Science Index (ProQuest)
44Engineering Index (ProQuest)
45Environmental Science Collection (ProQuest)
46Engineering Collection (ProQuest)
sourceidproquest
recordidproquest859535509
issn
000029149
10002-9149
218791913
31879-1913
rsrctypearticle
creationdate2011
addtitleThe American Journal of Cardiology
searchscope
01000273
11005660
21006759
31006761
41006762
51006763
61006993
71007015
81007067
91007107
101007443
111007555
121007899
131007945
141008005
151008886
161009127
171009384
1810000004
1910000005
2010000013
2110000015
2210000020
2310000022
2410000025
2510000034
2610000038
2710000039
2810000041
2910000043
3010000047
3110000050
3210000053
3310000064
3410000117
3510000118
3610000119
3710000120
3810000155
3910000156
4010000157
4110000158
4210000162
4310000164
4410000198
4510000209
4610000217
4710000234
4810000238
4910000250
5010000253
5110000255
5210000256
5310000257
5410000258
5510000259
5610000260
5710000265
5810000270
5910000271
6010000281
6110000300
6210000302
6310000348
6410000349
6510000350
6610000353
6710000354
6810000356
6910000360
70proquest
scope
01000273
11005660
21006759
31006761
41006762
51006763
61006993
71007015
81007067
91007107
101007443
111007555
121007899
131007945
141008005
151008886
161009127
171009384
1810000004
1910000005
2010000013
2110000015
2210000020
2310000022
2410000025
2510000034
2610000038
2710000039
2810000041
2910000043
3010000047
3110000050
3210000053
3310000064
3410000117
3510000118
3610000119
3710000120
3810000155
3910000156
4010000157
4110000158
4210000162
4310000164
4410000198
4510000209
4610000217
4710000234
4810000238
4910000250
5010000253
5110000255
5210000256
5310000257
5410000258
5510000259
5610000260
5710000265
5810000270
5910000271
6010000281
6110000300
6210000302
6310000348
6410000349
6510000350
6610000353
6710000354
6810000356
6910000360
70proquest
lsr43
01000273false
11005660false
21006759false
31006761false
41006762false
51006763false
61006993false
71007015false
81007067false
91007107false
101007443false
111007555false
121007899false
131007945false
141008005false
151008886false
161009127false
171009384false
1810000004false
1910000005false
2010000013false
2110000015false
2210000020false
2310000022false
2410000025false
2510000034false
2610000038false
2710000039false
2810000041false
2910000043false
3010000047false
3110000050false
3210000053false
3310000064false
3410000117false
3510000118false
3610000119false
3710000120false
3810000155false
3910000156false
4010000157false
4110000158false
4210000162false
4310000164false
4410000198false
4510000209false
4610000217false
4710000234false
4810000238false
4910000250false
5010000253false
5110000255false
5210000256false
5310000257false
5410000258false
5510000259false
5610000260false
5710000265false
5810000270false
5910000271false
6010000281false
6110000300false
6210000302false
6310000348false
6410000349false
6510000350false
6610000353false
6710000354false
6810000356false
6910000360false
startdate20110315
enddate20110315
citationpf 833 vol 107 issue 6
lsr30VSR-Enriched:[doi, pages, pqid]
sort
titleLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
authorApplegate, Robert ; Yaqub, Manejeh ; Hermiller, James ; Sood, Poornima ; Yu, Shui ; Doostzadeh, Julie ; Williams, Jerome ; Farhat, Naim ; Caputo, Ronald ; Lansky, Alexandra ; Cutlip, Donald ; Sudhir, Krishnankutty ; Stone, Gregg
creationdate20110315
lso0120110315
facets
frbrgroupid9094881868960613486
frbrtype5
languageeng
creationdate2011
topic
0United States–Us
1Cardiovascular Disease
2Patient Safety
3Clinical Trials
4Stents
5Comparative Analysis
6Cardiology
collection
0Medical Database
1Health & Medical Collection (Alumni edition)
2Medical Database (Alumni edition)
3Nursing & Allied Health Database (Alumni edition)
4Health & Medical Collection
5Nursing & Allied Health Database
6Sports Medicine and Education Index
7Research Library China
8Engineering Research Database
9Technology Research Database
10ProQuest Nursing & Allied Health Source
11ProQuest Research Library
12ProQuest Biological Science Collection
13ProQuest Central
14ProQuest Engineering Collection
15ProQuest Environmental Science Collection
16ProQuest Hospital Collection
17ProQuest Natural Science Collection
18ProQuest Technology Collection
19Research Library (Alumni edition)
20Hospital Premium Collection (Alumni edition)
21ProQuest SciTech Collection
22ProQuest Health & Medical Complete
23ProQuest Medical Library
24Physical Education Index
25Agricultural & Environmental Science Database
26Biological Science Database
27Materials Science & Engineering Database
28Natural Science Collection
29ProQuest Central (new)
30ProQuest Central K-12
31ProQuest Central Korea
32Research Library Prep
33SciTech Premium Collection
34Technology Collection
35Health Research Premium Collection
36Health Research Premium Collection (Alumni edition)
37ProQuest Central Essentials
38ProQuest Central China
39ProQuest One Academic
40Environmental Science Index (ProQuest)
41Biological Science Index (ProQuest)
42Engineering Index (ProQuest)
43Environmental Science Collection (ProQuest)
44Engineering Collection (ProQuest)
prefilterarticles
rsrctypearticles
creatorcontrib
0Applegate, Robert
1Yaqub, Manejeh
2Hermiller, James
3Sood, Poornima
4Yu, Shui
5Doostzadeh, Julie
6Williams, Jerome
7Farhat, Naim
8Caputo, Ronald
9Lansky, Alexandra
10Cutlip, Donald
11Sudhir, Krishnankutty
12Stone, Gregg
jtitleAmerican Journal of Cardiology
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Applegate
1Yaqub
2Hermiller
3Sood
4Yu
5Doostzadeh
6Williams
7Farhat
8Caputo
9Lansky
10Cutlip
11Sudhir
12Stone
aufirst
0Robert
1Manejeh
2James
3Poornima
4Shui
5Julie
6Jerome
7Naim
8Ronald
9Alexandra
10Donald
11Krishnankutty
12Gregg
auinit1
0R.
1M.
2J.
3P.
4S.
5N.
6A.
7D.
8K.
9G.
au
0Applegate, Robert
1Yaqub, Manejeh
2Hermiller, James
3Sood, Poornima
4Yu, Shui
5Doostzadeh, Julie
6Williams, Jerome
7Farhat, Naim
8Caputo, Ronald
9Lansky, Alexandra
10Cutlip, Donald
11Sudhir, Krishnankutty
12Stone, Gregg
atitleLong-Term (Three-Year) Safety and Efficacy of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents (from the SPIRIT III Trial)
jtitleThe American Journal of Cardiology
risdate20110315
volume107
issue6
spage833
issn00029149
eissn18791913
formatjournal
genrearticle
ristypeJOUR
abstractThe safety and efficacy of the XIENCE V everolimus-eluting stent (EES) compared to the Taxus Express paclitaxel-eluting stent (PES) has been demonstrated through 2 years in the SPIRIT II and III randomized clinical trials, but limited longer-term data have been reported. In the SPIRIT III trial, 1,002 patients with up to 2 lesions in 2 coronary arteries were randomized 2:1 to EESs versus PESs at 65 United States sites. At completion of 3-year follow-up, treatment with EES compared to PES resulted in a significant 30% decrease in the primary clinical end point of target vessel failure (cardiac death, myocardial infarction, or ischemic-driven target vessel revascularization, 13.5% vs 19.2%, hazard ratio 0.70, 95% confidence interval 0.50 to 0.96, p = 0.03) and a 43% decrease in major adverse cardiovascular events, cardiac death, myocardial infarction, or ischemic-driven target lesion revascularization (9.1% vs 15.7%, hazard ratio 0.57, 95% confidence interval 0.39 to 0.83, p = 0.003). In...
copNew York
pubElsevier Limited
urlhttp://search.proquest.com/docview/859535509/
doi10.1016/j.amjcard.2010.10.069
pages833-840
date2011-03-15